Cellular and Molecular Mechanisms of MEK1 Inhibitor–Induced Cardiotoxicity

BACKGROUND: Trametinib is a MEK1 (mitogen-activated extracellular signal-related kinase kinase 1) inhibitor used in the treatment of BRAF (rapid accelerated fibrosarcoma B-type)–mutated metastatic melanoma. Roughly 11% of patients develop cardiomyopathy following long-term trametinib exposure. Altho...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Tyler C., Arhontoulis, Dimitrios C., Morningstar, Jordan E., Hyams, Nathaniel, Stoddard, Andrew, Springs, Kendra, Mukherjee, Rupak, Helke, Kris, Guo, Lilong, Moore, Kelsey, Gensemer, Cortney, Biggs, Rachel, Petrucci, Taylor, Kwon, Jennie, Stayer, Kristina, Koren, Natalie, Harvey, Andrew, Holman, Heather, Dunne, Jaclyn, Fulmer, Diana, Vohra, Ayesha, Mai, Le, Dooley, Sarah, Weninger, Julianna, Vaena, Silvia, Romeo, Martin, Muise-Helmericks, Robin C., Mei, Ying, Norris, Russell A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700254/
https://www.ncbi.nlm.nih.gov/pubmed/36444237
http://dx.doi.org/10.1016/j.jaccao.2022.07.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700254/
https://www.ncbi.nlm.nih.gov/pubmed/36444237
http://dx.doi.org/10.1016/j.jaccao.2022.07.009

Ejemplares similares